Cynata Therapeutics Ltd Ordinar(CYYNF)

Description: Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.

---

Keywords: Biotechnology Life Sciences Biology Surgery Partnership Cell Therapy Cell Biology Asthma Neurosurgery College Fuji Artery Mesenchymal Stem Cell Acute Respiratory Distress Syndrome Brain Cancer A Therapeutic Coronary Artery Disease Artery Disease Host Disease Heart Attack Graft Versus Host Disease Mesoblast Respiratory Distress Syndrome Stem Cell Therapies Fujifilm Harvard Cymer Monash University Cymerus Technology Treatment Of Graft Versus Host Disease

---

Home Page: www.cynata.com

100 Cubitt Street
Cremorne, VIC 3121
Australia
Phone: 61 3 7067 6940

---

Officers

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)